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Objective: To compare the effect of Delayed Cord Clamping (DCC) to Immediate Cord
Clamping (ICC) on phototherapy treatment in a cohort of cesarean-delivered newborns
with AB0-alloimmunization.
Study Design: In a retrospective cohort study neonates with Gestational Age (GA)
≥ 35 weeks and diagnosed with AB0-alloimmunization before implementation of DCC
(ICC group) were compared with neonates born after implementation (DCC group).
The primary outcome was the need for phototherapy. Secondary outcomes included
hospital stay, readmission rate, need for extra intravenous fluids, maximum bilirubin
concentration, and hours of life at bilirubin peak. We used regression models to adjust
for weight loss, type of feeding, birth weight, and gestational age.
Results: In total 336 neonates were included, of which 192 neonates in the ICC group
and 144 in the DCC group. There were no differences in basic characteristics between
the two groups except for birth weight (ICC 3193 ± 468 g vs. DCC 3053 ± 446 g,
p= 0.01) and GA (ICC 38.2± 1 weeks of GA, vs. DCC 37.9± 1 weeks of GA; p= 0.01).
When adjusted for confounding factors, after implementation of DCC, significantly more
infants with AB0 alloimmunization needed phototherapy (22.4% vs. 36.8%, RR 1.61 CI:
1.15–2.28; p = 0.006; Number Needed to Harm 7), needed to stay longer in hospital
(20.3% vs. 30.5%, RR 1.53 CI: 1.05–2.23; p = 0.03). The maximum bilirubin was higher
(11.4 ± 4.0mg/dl vs. 12.9 ± 3.5 mg/dl, p < 0.001) and occurred later [74 (67–92) hours
vs. 84 (70–103) hours; p = 0.04]. There was no difference in the need for intravenous
fluids (1.6% vs. 4.9%; not significant) and readmissions (1.6% vs. 3.5%; not significant).
Conclusion: Infants with AB0 alloimmunization needed more often phototherapy and
were admitted longer after implementation of DCC policy. Further studies are needed to
see whether the benefit of DCC outweighs the increased morbidity, admission days, and
related hospital costs.
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INTRODUCTION
Delayed Cord Clamping (DCC) in term newborns improves
iron stores in infancy, and most international guidelines now
recommend at least 30–60 s of DCC in term and preterm
newborns not requiring resuscitation (1–3). There are no relevant
side effects associated with DCC, except for a 2% increase in term
infants requiring phototherapy (4).
Hemolytic Disease of the Newborn (HDN) increases the risk
of pathologic jaundice. Rhesus disease is responsible for about
114,000 neonatal deaths and 76,000 cases of kernicterus per
year worldwide (5), especially in low-income countries where
antenatal anti-D prophylaxis is not guaranteed. Rhesus disease
was excluded in most DCC trials, as it was likely that DCC
increased the risk for hyperbilirubinemia due to the higher
amount of opsonized Red Blood Cells (RBC) transfused from
the placenta to the newborn that could undergo hemolysis. In
a retrospective study (6) authors observed that 30 s of DCC
in a group of neonates with fetal Rh-disease reduced the
need for exchange transfusion without increasing the rate of
pathologic hyperbilirubinemia when compared to Immediate
Cord Clamping (ICC). However, the results were not conclusive
due to the differences in Gestational Age (GA), birth weight,
mode of delivery and, management of jaundice between the two
study periods.
Hemolytic disease of the newborn due to AB0-
alloimmunization shares the same biological basis of Rh-disease
but is more common and less severe.
From January 2015, our Unit adopted a protocol for the
management of umbilical cord clamping; we recommend to
clamp the umbilical cord after 1min from birth in cases
of Cesarean-Delivered (CD) term and late preterm newborns
not requiring resuscitation. Our study aimed to retrospectively
analyze the need for phototherapy in two cohorts of newborns
with AB0 alloimmunization, before and after the implementation
of DCC in our clinical practice.
MATERIALS AND METHODS
We conducted a retrospective, single-center cohort study at
the baby nursery of the Department of Clinical Sciences and
Community Health, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico in Milan, Italy. Ethics committee approval
was not required for this non-interventional study.
A protocol for the management of umbilical cord clamping
was implemented in January 2015 in our Unit, where cord
clamping at 1min for cesarean (CS) and between 1 and 3min
for vaginally delivered infants (term and late preterm) was
recommended. Intravenous oxytocin was given after the cord
was clamped. Neonatal caregivers were not standardly present for
vaginal deliveries and timing of cord clamping was not formally
assessed and recorded. During CS, the timing of cord clamping
was observed and recorded by the neonatal caregivers. For this
reason, we only included infants born by CS. Before 2015, in CD
newborns, the umbilical cord was clamped before 10 s from birth.
Milking of the umbilical cord in healthy term and late preterm
newborns was not performed in our Unit. Contra-indications to
DCC were fetal hydrops, fetal Rh-alloimmunization, maternal
HIV or HCV with positive viremia, monochorionic twins and
newborns requiring immediate resuscitation.
Per protocol, cord Direct Antiglobulin Test (c-DAT) was
performed at each delivery immediately after birth; if positive,
we assessed neonatal blood group. Maternal blood group was
obtained from obstetric charts. We compared a cohort of
neonates who were diagnosed with AB0 alloimmunization and
were born by CS before (December 2012 to December 2013; ICC
group) and after (October 2015 to October 2017; DCC group)
implementation of DCC.
We included in the analysis all neonates admitted to our
nursery with GA ≥ 35 weeks since hyperbilirubinemia is
uniformly managed in our Unit according to the American
Academy of Pediatrics (AAP) guidelines (7). Exclusion criteria
for the study were the following: GA < 35 weeks, emergency
cesarean section, familial risk factors for pathological jaundice
(e.g., spherocytosis, glucose-6-phosphate dehydrogenase
deficiency, and Gilbert’s syndrome), documented Rh-
alloimmunization, neonatal cholestatic jaundice, genetic
syndromes, twins, symptomatic polycythemia, hypoglycemia,
sepsis, transient tachypnea of newborns, and any case of
hospitalization in NICU for reasons unrelated to jaundice.
The primary outcome was hyperbilirubinemia requiring
phototherapy during hospitalization. Secondary outcomes were:
(1) Hours of phototherapy, (2) Extra-days of hospitalization due
to jaundice, defined as eachmore day of hospitalization following
4 days admission after CS delivery because of phototherapy or
bilirubin concentration in the high-risk zone, according to AAP
and Bhutani nomograms, (3) Hospital readmission for jaundice,
(4) Need for intravenous (IV) Infusion, (5) Immunoglobulin
therapy, and (6)Maximum bilirubin concentration (mg/dl). Data
were collected from the electronic medical charts (Neocare, I&T
Informatica e Tecnologia Srl, Italy), available in our Unit.
We carefully assessed all neonates with positive c-DAT for
jaundice, by checking serum bilirubin on capillary gas analysis
within the first 12 h of life and subsequently according to
clinical needs. Themanagement of hyperbilirubinemia, including
the need for phototherapy, IV immunoglobulin, exchange
transfusion, and the criteria for phototherapy discontinuation
were assessed, according to AAP guidelines (7). Per local
protocol, all patients with AB0 alloimmunization were treated
with high-intensity phototherapy.
Venous blood samples were not routinely performed in
healthy term and late preterm newborns. In the case of
hematocrit >70% on capillary samples, we performed a venous
cell blood count to check for polycythemia (defined as central
venous hematocrit higher than 65% or a hemoglobin value above
22 g/dL).
Before discharge, we estimated the risk of developing severe
hyperbilirubinemia according to Buthani nomogram; infants in
the “high-risk zone” were monitored for at least 24 h (8). Starting
and stopping of phototherapy was retrospectively reviewed by
the authors to minimize possible errors in data collection, arising
from protocol violations during clinical practice. Clinical and
biochemical data collection included: sex, GA, birth-weight,
small for gestational age < 3rd percentile according to Bertino’s
growth charts (9), weight loss (percentage), type of feeding
(exclusive breastfeeding, mixed or bottle feeding), East Asian
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race, and cephalohematoma or significant bruising. We collected
the first bilirubin concentration, the bilirubin concentration at
Newborn Screening (NS), between 48 and 72 h after birth, the
maximum bilirubin concentration, and the hours of life at each
determination. Only values of total serum bilirubin or Capillary
Bilirubin (CB) were considered.
Categorical variables were expressed as a percentage and
quantitative variables as the mean ± Standard Deviation (SD)
or median with InterQuartile Range (IQR) in case of non-
normal distribution (Shapiro-Wilk test was performed to assess
normality of distribution). The two cohorts were compared using
the χ2-test (or Fisher exact test when expected cell frequency
was <5) for categorical variables and Mann-Whitney U-test for
quantitative variables. We performed univariate and multiple
Poisson regressionmodels with robust standard error to calculate
Risk Ratios (RR) with a 95% Confidence Intervals (CI) and
Risk Difference (RD) for selected categorical outcomes (10).
Linear or quantile regression models were used to calculate
mean or median differences between quantitative variables.
Multivariable models included gestational age, birth weight,
weight loss (0–7%, 7.1–10%, and >10%) and type of feeding
(exclusive breastfeeding, mixed, and bottle), all interfering with
bilirubin metabolism. For the primary outcome, we calculated
the Number Needed to Harm (NNH). Statistical analyses were
performed with Stata, version 14 (StataCorp, 2015).
RESULT
In total 336 infants were included in the study, of which 192
neonates in the ICC group and 144 in the DCC group. There were
no differences in basic characteristics between the two groups
except for birth weight (ICC 3193± 468 g vs. DCC 3053± 446 g,
p = 0.01) and GA (ICC 38.2 ± 1 weeks of GA, vs. DCC 37.9 ±
1 weeks of GA; p = 0.01; Table 1). The number of late preterm
and Small for Gestational Age (SGA) newborns were comparable
between the two groups.
Fifteen neonates in the ICC group (7.8%) and 11 neonates
in the DCC group (7.6%) had a capillary hematocrit higher
than 70%, but polycythemia was not confirmed by venous blood
samples. No patients showed clinical symptoms associated with
polycythemia.
After adjusting for gestational age, birth weight, weight loss,
and type of feeding, infants receiving phototherapy increased
after implementation of DCC (22.4% vs. 36.8% p = 0.006;
Table 2). The RR for phototherapy in the DCC group was 1.61
(95% CI: 1.15–2.28) with a RD of 14.4% (95% CI: 4.56–24.2) and
a NNH of 7. Infants had to stay longer in hospital and the number
of extra admission days due to jaundice increased (ICC 20.3% vs.
DCC 30.5%; RR 1.53, 95% CI: 1.05–2.23; p= 0.03), but there was
no difference in infants receiving IV infusion (ICC 1.6% vs. DCC
4.9%; p = 0.18), and hospital readmission (ICC 1.6% vs. DCC
3.5%; p = 0.21; Table 2). Immunoglobulin infusion was rarely
given in both groups (Table 2).
There were no differences in measurements of bilirubin,
except for the maximum bilirubin concentration (ICC 11.4 ±
4.0 mg/dl vs. DCC 12.9 ± 3.5 mg/dl; p < 0.001; Table 3).
TABLE 1 | Demographic features.
AB0 incompatibility
ICC group (n = 192) DCC group (n = 144) p-Value*
n (%) n (%)
SEX
Male 98 (51.0) 68 (47.2) 0.49
Female 94 (49.0) 76 (52.8)
GESTATIONAL AGE
GA <37 11 (5.7) 13 (9.0) 0.24
GA ≥37 181 (94.3) 131 (91.0)
GA (mean ± SD) 38.2 ± 1 37.9 ± 1 0.01
BIRTH WEIGHT
Birth weight (mean ±
SD)
3193 ± 468g 3053 ± 446g 0.01
SGA < 3rd percentile 5 (2.6) 4 (2.7) 0.92
WEIGHT LOSS (%)
0–7 48 (25.0) 46 (31.9) 0.16
7.1–10 97 (50.5) 69 (47.9) 0.64




113 (58.9) 69 (47.9) 0.05
Mixed feeding 63 (32.8) 61 (42.4) 0.07
Bottle feeding 16 (8.3) 14 (9.7) 0.66
Asian race 6 (3.1) 5 (3.4) 0.86
Cephalohematoma or
significant bruising
1 (0.5) 0 (0.0) 0.38
*Chi-squared test for categorical variables, Mann–Whitney U-test for quantitative
variables. GA, Gestational Age; DCC, Delayed Cord Clamping; ICC, Immediate Cord
Clamping; SD, Standard Deviation, SGA, Small for Gestational Age.
We observed a delayed peak of bilirubin in the DCC group (ICC
74 hours, IQR 67–92 vs. DCC 84 hours, IQR 70–103; p = 0.04)
compared to the ICC group. The ICC group required a longer
period of phototherapy compared to DCC (ICC 28 hours, IQR
15–43 vs. DCC 19 hours, IQR 9–51; p =0.07) but the DCC
newborns required more extra days of hospital stays (ICC 1 day,
IQR 1–3 vs. DCC 2 days, IQR 2–3; p= 0.007).
DISCUSSION
Our study compared delayed to immediate umbilical cord
clamping in a cohort of cesarean-delivered term and late
preterm newborns with AB0 alloimmunization. After adjustment
for potential confounding factors, we observed that more
infants needed phototherapy and needed to stay longer in
the hospital after DCC was implemented. The bilirubin
concentration was significantly higher in the DCC group,
and the peak occurred later. This is not a new finding,
meta-analysis comparing DCC vs. ICC in term infants also
demonstrated an increased risk for hyperbilirubinemia and
phototherapy (4). It was argued that the benefits at later age
outweigh the risk for hyperbilirubinemia. However, in our
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n (%) n (%)
Phototherapy 43 (22.4) 53 (36.8) 14.4 (4.56, 24.2) 1.64 (1.17, 2.30) 1.61 (1.15, 2.28) 0.004 0.006
Longer hospital stay (Pts) 39 (20.3) 44 (30.5) 10.2 (0.81, 19.7) 1.50 (1.04, 2.18) 1.53 (1.05, 2.23) 0.03 0.03
IV infusion 3 (1.6) 7 (4.9) 3.29 (0.63, 7.22) 3.11 (0.82, 11.8) 2.63 (0.64, 10.8) 0.08 0.18
Hospital readmission 3 (1.6) 5 (3.5) 1.90 (1.56, 5.37) 2.22 (0.54, 9.15) 2.47 (0.60, 10.2) 0.26 0.21
Immunoglobulin 2 (1.0) 1 (0.7) −0.34 (−2.32, 1.63) 0.67 (0.06, 7.28) 0.54 (0.07, 3.93) 0.73 0.54
*The ICC group was defined as a reference; **Risk ratios and 95% confidence intervals from multivariable Poisson regression models with robust standard error adjusted for birth weight,
gestational age, weight loss (0–7%, 7.1–10%, and >10%), and type of feeding (exclusive breastfeeding, mixed, and bottle); CI, Confidence Interval; DCC, Delayed Cord Clamping; ICC,
Immediate Cord Clamping; IV, Intravenous; Pts, Patients; RD, Risk Difference; RR, Risk Ratio.
TABLE 3 | Measurements.
AB0 incompatibility Mean or median difference
crude (95% CI)












28 (15, 43) 19 (9, 51) −9.0 (−23.3, 5.25) −10.0 (−21.2, 0.87) 0.21 0.07
1st CB value, mg/dl, mean ± SD 8.8 ± 3.0 8.3 ± 2.8 −0.5 (−1.18, 0.15) −0.3 (−0.97, 0.37) 0.13 0.38
1st CB value, hours, median
(IQR)
47 (30, 67.5) 42 (26, 69) −5.0 (−17.5, 9.47) 2.0 (−7.69, 11.7) 0.56 0.85
Maximum bilirubin value, mg/dl,
mean ± SD
11.4 ± 4.0 12.9 ± 3.5 1.5 (0.73, 2.37) 1.6 (0.78, 2.45) <0.0001 <0.0001
Maximum bilirubin, hours,
median (IQR)
74 (67, 92) 84 (70, 103) 10 (−0.64, 20.6) 9 (0.21, 17.8) 0.01 0.04
Bilirubin value at NS, mg/dl,
mean ± SD
10.8 ± 3.1 11.1 ± 2.5 0.3 (−0.35, 0.97) 0.4 (−0.26, 1.08) 0.35 0.23
Extra days of hospital stay, days,
median (IQR)
1 (1, 3) 2 (2, 3) 1 (−0.15, 1.50) 1 (−0.27, 1.72) 0.11 0.007
*The ICC group was defined as a reference; **Mean or median differences and 95% confidence intervals from multivariable linear or quantile regression models adjusted for birth
weight, gestational age, weight loss (0–7%, 7.1–10%, and >10%), and type of feeding (exclusive breastfeeding, mixed, and bottle); mean ± standard deviation for normally distributed
data; median (IQR) for not normally distributed data; CB, Capillary Bilirubin; CI, Confidence Interval; DCC, Delayed Cord Clamping; dl, deciliter; ICC, Immediate Cord Clamping; IQR,
InterQuartile Range; mg, milligrams; NS, Newborn Screening; SD, Standard Deviation.
study, the number of infants needing phototherapy almost
doubled and with the extra admission days, this would have a
considerable impact on hospital resources and costs. Although
phototherapy is safe and a non-invasive therapy, it is possible
that we should reconsider the benefits of DCC in infants with
AB0-alloimmunization.
HDN is an alloimmune disorder caused by transplacentally
transmitted maternal immunoglobulin G antibodies that bind
to paternally inherited antigens present on fetal RBC resulting
in increased hemolysis, bilirubin concentration, and need for
phototherapy (11). HDN due to AB0-incompatibility is more
common than Rh-disease but is clinically less severe due to a
weaker expression of AB0 antigens at birth. Many researchers
excluded Rhesus disease fromDCC trials, as there was a common
belief that DCC could increase the risk for neonatal jaundice in
these patients (4). This effect would have a biological plausibility,
as a higher amount of opsonized RBC that passes from the
placenta to the newborn could undergo hemolysis.
Garabedian et al. (5) compared DCC with ICC in a cohort
study with neonates with Rh-alloimmunization, who were
transfused in utero. They reported that the DCC group were less
anemic, had higher hemoglobin concentration in the first hour
after birth, and required less exchange transfusion postnatally.
In contrast to our findings, they observed no differences in
maximum bilirubin levels, need for intensive phototherapy and
phototherapy duration between the two cohorts. However, it
is difficult to interpret the results of Garabedian et al.; the
differences in hyperbilirubinemia management, GA and rate of
vaginal deliveries likely influenced the outcome. Vaginal delivery
is associated with higher hemoglobin values at birth, compared to
CD (12), and could explain the higher hemoglobin concentration
in the DCC group.
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The bilirubin concentration was similar between the cohorts
in the first 2 days of life, but maximum bilirubin concentration
was significantly higher and occurred later in the DCC group.
One possible explanation for this observation could be related
to the improved neonatal volemia and urinary output associated
with DCC (13, 14); the combined effect of dilution and increased
bilirubin urinary excretion in the first days of life may have
postponed the peak of bilirubinemia in the DCC group. We
speculate that this delayed peak in bilirubin resulted in a lower
duration of phototherapy, but also prolonged the admission in
the hospital. Although more infants needed phototherapy, the
duration was shorter as the threshold for phototherapy would be
higher after the first days after birth when the bilirubin peaked
later. However, this would also lead to a longer stay in the
hospital.
Our results suggest that DCC in infants with hemolytic
jaundice could increase morbidity. AB0 alloimmunization could
be considered a proxy for Rh alloimmunization since they share
a common pathophysiological basis. Rhesus disease affects about
370,000 newborns worldwide with approximately 114,000 cases
of neonatal deaths and 76,000 cases of kernicterus per year,
most of them occurring in low-income countries (6). Given the
morbidity and mortality of Rhesus disease, randomized trials
are needed to assess the safety of delayed cord clamping in this
population.
Our study has certain limitations and caution is needed
when interpreting the results. Hemoglobin level after birth was
not routinely evaluated and the effect of placental transfusion
on hemoglobin and hematocrit could not be retrospectively
evaluated.We are thus unaware of the incidence of asymptomatic
polycythemia in our cohort.
However, according to our knowledge, the meta-analysis by
Mc Donald et al. (five trials) reported no difference in the
incidence of polycythemia between the early and late cord
clamping groups (RR 0.39 95% CI 0.12 to 1.27; 1025 infants)
(4) and authors did not specifically recommend to check DCC
newborns for polycythemia.
Differently, Hutton et al. reported an higher incidence
of asymptomatic polycythemia associated with delayed cord
clamping in term (15) newborns, without an increased risk for
phototherapy or partial exchange transfusion.
The lower birth weight in the DCC group does not confirm an
increase in placental volume. Although there was no difference
in the number of late preterm between groups, infants in the
DCC group were slightly younger, and probably influenced the
difference in birth weight.
Animal models and clinical studies showed a reduced
placental transfusion after cesarean delivery (16–18); however,
Andersson et al. (19) have recently demonstrated that 30-s DCC
in elective CD newborns resulted in similar iron status at 4
months of age if compared to 3-min DCC in vaginal deliveries.
As we included only infants born by CS, it is possible that
we underestimated the effect of DCC on phototherapy. Also,
immaturity could have played a role; however, late preterm
neonates were equally distributed in the two groups.
The DAT has a poor positive predictive value for identifying
newborns at risk of clinically significant hyperbilirubinemia
(20), and a positive DAT does not mean that increased
hemolysis will occur. Suggested criteria for HDN are blood
group incompatibility plus the demonstration of hemolysis
(elevate reticulocyte count and lactic dehydrogenase
enzyme concentration, progressive anemia, transient
microspherocytosis) and a positive DAT (20). However,
elevated reticulocyte count and microspherocytosis are common
hematological features in the first days of life, and their
interpretation is not univocal. Serial venous blood samples
for full blood examination may be too invasive to document
progressive anemia in a nursery setting. Therefore, it is a
prevailing attitude in clinical practice to consider an infant with
a positive DAT to be at higher risk for significant jaundice. AAP
charts for the management of neonatal hyperbilirubinemia (7)
reduced the threshold for treatment in positive DAT newborns
and Bhutani Nomogram (8) for the designation of the risk of
hyperbilirubinemia at discharge considered AB0 incompatibility
as a risk factor for significant jaundice. If future studies confirm
the association between DCC and a delayed peak of bilirubin
in AB0 immunization, the nomograms for the designation
of the risk of significant hyperbilirubinemia may need to be
revised.
CONCLUSION
To our knowledge, this retrospective study is the first that
analyzed the effect of DCC in a cohort of infants at increased
risk for pathological jaundice due to AB0 alloimmunization. In
infants with AB0 alloimmunization, we observed an association
between DCC, need for phototherapy, and prolonged admission.
Since we did not include VD, where the effect of placental
transfusion is larger, it is possible we underestimated the effect
of DCC. Adequately designed studies in a randomized setting
are needed to confirm or refute our findings, but centers should
balance the benefit of DCC against the increased risk, resources
and costs, especially in infants with alloimmunization.
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